The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data.

WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study Gr; Martin A Adjuik; Richard Allan; Anupkumar R Anvikar; Elizabeth A Ashley; Mamadou S Ba; Hubert Barennes; Karen I Barnes; Quique Bassat; Elisabeth Baudin; +97 more... Anders Björkman; François Bompart; Maryline Bonnet; Steffen Borrmann; Philippe Brasseur; Hasifa Bukirwa; Francesco Checchi ORCID logo; Michel Cot; Prabin Dahal; Umberto D'Alessandro ORCID logo; Philippe Deloron; Meghna Desai; Graciela Diap; Abdoulaye A Djimde; Grant Dorsey; Ogobara K Doumbo; Emmanuelle Espié; Jean-Francois Etard; Caterina I Fanello; Jean-François Faucher; Babacar Faye; Jennifer A Flegg; Oumar Gaye; Peter W Gething; Raquel González; Francesco Grandesso; Philippe J Guerin; Jean-Paul Guthmann; Sally Hamour; Armedy Ronny Hasugian; Simon I Hay; Georgina S Humphreys; Vincent Jullien; Elizabeth Juma; Moses R Kamya; Corine Karema; Jean R Kiechel; Peter G Kremsner; Sanjeev Krishna; Valérie Lameyre; Laminou M Ibrahim; Sue J Lee; Bertrand Lell; Andreas Mårtensson; Achille Massougbodji; Hervé Menan; Didier Ménard; Clara Menéndez; Martin Meremikwu; Clarissa Moreira; Carolyn Nabasumba; Michael Nambozi; Jean-Louis Ndiaye; Frederic Nikiema; Christian Nsanzabana; Francine Ntoumi; Bernhards R Ogutu; Piero Olliaro; Lyda Osorio; Jean-Bosco Ouédraogo; Louis K Penali; Mbaye Pene; Loretxu Pinoges; Patrice Piola; Ric N Price; Cally Roper ORCID logo; Philip J Rosenthal; Claude Emile Rwagacondo; Albert Same-Ekobo; Birgit Schramm; Amadou Seck; Bhawna Sharma; Carol Hopkins Sibley; Véronique Sinou; Sodiomon B Sirima; Jeffery J Smith; Frank Smithuis; Fabrice A Somé; Doudou Sow; Sarah G Staedke ORCID logo; Kasia Stepniewska; Todd D Swarthout; Khadime Sylla; Ambrose O Talisuna; Joel Tarning; Walter RJ Taylor; Emmanuel A Temu; Julie I Thwing; Emiliana Tjitra; Roger CK Tine; Halidou Tinto; Michel T Vaillant; Neena Valecha; Ingrid Van den Broek; Nicholas J White; Adoke Yeka; Issaka Zongo; (2015) The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC medicine, 13 (1). 66-. ISSN 1741-7015 DOI: 10.1186/s12916-015-0301-z
Copy

BACKGROUND: Artesunate-amodiaquine (AS-AQ) is one of the most widely used artemisinin-based combination therapies (ACTs) to treat uncomplicated Plasmodium falciparum malaria in Africa. We investigated the impact of different dosing strategies on the efficacy of this combination for the treatment of falciparum malaria. METHODS: Individual patient data from AS-AQ clinical trials were pooled using the WorldWide Antimalarial Resistance Network (WWARN) standardised methodology. Risk factors for treatment failure were identified using a Cox regression model with shared frailty across study sites. RESULTS: Forty-three studies representing 9,106 treatments from 1999-2012 were included in the analysis; 4,138 (45.4%) treatments were with a fixed dose combination with an AQ target dose of 30 mg/kg (FDC), 1,293 (14.2%) with a non-fixed dose combination with an AQ target dose of 25 mg/kg (loose NFDC-25), 2,418 (26.6%) with a non-fixed dose combination with an AQ target dose of 30 mg/kg (loose NFDC-30), and the remaining 1,257 (13.8%) with a co-blistered non-fixed dose combination with an AQ target dose of 30 mg/kg (co-blistered NFDC). The median dose of AQ administered was 32.1 mg/kg [IQR: 25.9-38.2], the highest dose being administered to patients treated with co-blistered NFDC (median = 35.3 mg/kg [IQR: 30.6-43.7]) and the lowest to those treated with loose NFDC-25 (median = 25.0 mg/kg [IQR: 22.7-25.0]). Patients treated with FDC received a median dose of 32.4 mg/kg [IQR: 27-39.0]. After adjusting for reinfections, the corrected antimalarial efficacy on day 28 after treatment was similar for co-blistered NFDC (97.9% [95% confidence interval (CI): 97.0-98.8%]) and FDC (98.1% [95% CI: 97.6%-98.5%]; P = 0.799), but significantly lower for the loose NFDC-25 (93.4% [95% CI: 91.9%-94.9%]), and loose NFDC-30 (95.0% [95% CI: 94.1%-95.9%]) (P < 0.001 for all comparisons). After controlling for age, AQ dose, baseline parasitemia and region; treatment with loose NFDC-25 was associated with a 3.5-fold greater risk of recrudescence by day 28 (adjusted hazard ratio, AHR = 3.51 [95% CI: 2.02-6.12], P < 0.001) compared to FDC, and treatment with loose NFDC-30 was associated with a higher risk of recrudescence at only three sites. CONCLUSIONS: There was substantial variation in the total dose of amodiaquine administered in different AS-AQ combination regimens. Fixed dose AS-AQ combinations ensure optimal dosing and provide higher antimalarial treatment efficacy than the loose individual tablets in all age categories.


picture_as_pdf
The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria_GOLD VoR.pdf
subject
Published Version
Available under Creative Commons: 3.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads